

| | |
|----------|--------------------|
| Ref. No: | FOI1815 |
| Date: | 06/06/2025 |
| Subject: | Biologics (Gastro) |

REQUEST & RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 6
- Adalimumab Biosimilar 166
- Etrasimod 0
- Filgotinib 17
- Golimumab <5
- Infliximab – Remicade <5
- Infliximab Biosimilar 262
- Mirikizumab <5
- Ozanimod 3
- Risankizumab 21
- Tofacitinib 14
- Upadacitinib 27
- Ustekinumab – Stelara 10
- Ustekinumab Biosimilar 154
- Vedolizumab 108

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 0
- Adalimumab Biosimilar 20
- Etrasimod 0
- Filgotinib 0
- Golimumab <5
- Infliximab – Remicade 0
- Infliximab Biosimilar 21
- Mirikizumab 0
- Ozanimod 0
- Risankizumab 0
- Tofacitinib <5

- Upadacitinib <5
- Ustekinumab – Stelara 0
- Ustekinumab Biosimilar <5
- Vedolizumab 0

<5

Due to the low number of patients receiving the some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.